Drug eluting stent (DES) in-stent restenosis (ISR) is currently a challenging, seeing as it often requires repeat revascularization. The use of drug coated balloons (DCB) offers the advantage of delivering the drug without the need for re-stenting. This highlights the importance of the technological development of DCB, with diverse drug formulations and coating technologies. As...
Glycemic Control and Coronary Stent Failure
Diabetic patients have twice as high a risk of developing coronary artery disease (CAD). Additionally, CAD increases mortality risk. Patients with a history of percutaneous coronary intervention (PCI) tend to need repeat revascularization, even with second generation stents. To date, there are few studies assessing the role of glycemic control in stent failure, stent thrombosis,...
Coronary Angioplasty with Sirolimus Eluting Stents
At present, most percutaneous coronary intervention procedures (PCI) are done with drug eluting stents (DES). However, drug coated balloons (DCB) have shown benefits in restenosis and small vessel de novo lesions. Intravascular ultrasound (IVUS) has been shown effective in left main PCI and complex procedures, even though there is little infomration on its use for...
EuroPCR 2024 | 2 Year Outcomes of the New Sirolimus Eluting Bioadaptor vs Resolute Onyx Zotarolimus Elulting Stent
Stent related adverse events after the first year see a constant 2-3% annual increase, reaching 20% by year 5 and 50% by year 10. BIOADAPTADOR RCT outcomes at 12 months have shown the safety and efficacy of DynamX Bioadaptor, establishing new reference parameters in arterial viability restoration. The aim of this study was to report...
EuroPCR 2024 | DOCTORS-LM Trial: CTO Optimizes Stent Outcomes in Left Main Disease?
The aim of this randomized open study was to determine whether CTO guided left main percutaneous coronary intervention (PCI) is superior to fluoroscopy guided PCI, using fractional flow reserve (FFR) after stenting. The secondary outcomes were procedural success (successful implantation, malposition, edge dissection or stent collapse) and major adverse cardiovascular events (MACE) at one year....
Treatment of Recurrent In-Stent Restenosis with Drug-Eluting Stents: 10-Year Outcomes
In-stent restenosis (ISR) remains the main limitation in the percutaneous treatment of coronary artery disease, with a prevalence between 5% and 10% after implantation of latest-generation drug-eluting stents (DES). Therapeutic recommendations for it include the implantation of a new DES and the use of drug-coated balloons (DCB). The rate of recurrent ISR ranges from 10%...
AGENT-IDE: Drug Coated Balloons for Instent Restenosis
Drug eluting stents (DES) have improved considerably over the years, reducing the initial indices of instent restenosis (ISR) by roughly 5-10% a year in USA. However, DES failure might lead to neointimal hyperplasia and neoatherosclerosis, which increases the chance of developing chronic and acute coronary syndromes. Drug coated balloons (DCB), which administer anti-proliferative agents with...
Survey on Hemodynamics Centers in Latin America – SOLACI, Stent Save a Life! and South American Society of Cardiology Initiative
The treatment of ST-segment elevation myocardial infarction (STEMI) in Latin America is highly diverse. There are notable differences between countries and even among regions within a single country. It is clear that the treatment of STEMI is still an unmet need in our region. SOLACI and the Stent – Save a Life! Initiative in Latin...
Network Meta-Analysis of Complementary Imaging (IVUS/OCT + Conventional Angiography) for Coronary Stenting
Complementary imaging allows for the identification of numerous scenarios not visible with conventional angiography (ICA), both for the assessment of differential diagnoses and the improvement of percutaneous coronary intervention (PCI) outcomes. Advantages include assessment of plaque characteristics, vessel plaque burden, stent edge dissection, vessel diameter, and correct apposition, among others. While intravascular ultrasound (IVUS) was...
Recurrent Revascularization at 10 Years after Percutaneous Treatment of DES In-Stent Restenosis
In stent restenosis (ISR) continues to be the main limitation to the percutaneous treatment of coronary artery disease, with 5 to 10% prevalence after new generation DES stenting. Guideline recommendations for this intervention include new DES stenting and the use of drug coated balloons (DCB). Recurrent ISR stenting rate ranges between 10 and 40%, and...